FindTrial
Sign In

Comparing Sugammadex in reversing muscle relaxation from Rocuronium and Vecuronium during operations

Efficacy of Sugammadex in reversal of Rocuronium versus Vecuronium induced Neuromuscular Blockade - a randomized controlled double blind trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093785
Enrollment
62
Registered
2025-08-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Sugammadex in reversal of Rocuronium induced Neuromuscular Blockade: Group 1 - 2mg/kg of Sugammadex will be administered for reversal of Rocuronium induced neuromuscular blockade. Cont

Sponsors

Gunnam Lakshmi Prathyusha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients posted for Elective Surgery under General Anaesthesia. American Society of Anaesthesiologists (ASA) physical status I and II.

Exclusion criteria

Exclusion criteria: Neuromuscular disorder. Suspected renal insufficiency. Significant hepatic dysfunction. Allergy to one of the drugs used in this study. Pregnant and breast-feeding. Surgery more than 2 hours

Design outcomes

Primary

MeasureTime frame
To assess the time (in minutes) needed to achieve a TOF ratio of greater than 0.9 after administration of sugammadex. Timepoint: To assess the time (in minutes) needed to achieve a TOF ratio of greater than 0.9 after administration of sugammadex.—

Secondary

MeasureTime frame
To assess Hemodynamic Parameters (SBP, DBP, MAP, HR, SP02) at 2, 5, 10, 15, 30, 60, 120 minutes. Incidence of adverse effects like Hypotension, Bradycardia, PONV. Timepoint: 2, 5, 10, 15, 30, 60, 120 minutes.—

Countries

India

Contacts

Public ContactDr Ayesha Pattnaik

Kalinga Institute Of Medical Sciences

drriteshroy@yahoo.com7008016886

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026